<DOC>
	<DOCNO>NCT01773473</DOCNO>
	<brief_summary>The purpose study determine efficacy safety insulin Lispro Mix25 ( LM25 ) compare insulin Lispro Mix50 ( LM50 ) insulin starter participant Type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Comparison Insulin Mix25 Versus Mix50</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Have diagnosis Type 2 Diabetes Mellitus ( T2DM ) least 6 month Have take sulfonylurea , biguanide , thiazolidinedione , alphaglucosidase inhibitor , glinide , dipeptidyl peptidase IV inhibitor , combination Have qualify hemoglobin A1c ( HbA1C ) value ≥7.0 % ≤11.0 % screening Have body mass index ( BMI ) ≥18.5 &lt; 35.0 kilogram per square meter ( kg/m² ) Have give write informed consent participate study accordance local regulation ethical review board ( ERB ) govern study site Have diagnosis type 1 diabetes Have 1 episode severe hypoglycemia within 6 month screen Have follow cardiovascular condition within 3 month prior screen : acute myocardial infarction , New York Heart Association ( NYHA ) class III class IV heart failure , cerebrovascular accident ( stroke ) Have obvious clinical sign symptom liver disease , acute chronic hepatitis , alanine aminotransferase level ≥3.0 time upper limit reference range screening , determined central laboratory Have estimate creatinine clearance ( CrCl ) , CockcroftGault formula &lt; 30 milliliter per minute ( mL/min ) , determined central laboratory screen Have evidence significant , active , uncontrolled endocrine autoimmune abnormality , judge investigator Have active untreated malignancy remission clinically significant malignancy &lt; 5 year Have condition ( , know drug alcohol abuse psychiatric disorder ) may prevent participant follow completing protocol Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>